A Comparative Study of Intraocular Pressure Control Using Selective Laser Trabeculoplasty
The goal of this clinical trial is to compare the short-term efficacy and safety of selective laser trabeculoplasty (SLT) to 0.005% latanoprost eye drops in lowering intraocular pressure (IOP) as primary therapy in treatment-naïve patients diagnosed as early to moderate primary open-angle glaucoma(POAG) or ocular hyper
| Condition(s) | Primary Open Angle Glaucoma or Ocular Hypertension |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The goal of this clinical trial is to compare the short-term efficacy and safety of selective laser trabeculoplasty (SLT) to 0.005% latanoprost eye drops in lowering intraocular pressure (IOP) as primary therapy in treatment-naïve patients diagnosed as early to moderate primary open-angle glaucoma(POAG) or ocular hypertension (OHT) in the Lagos State University Teaching Hospital, Ikeja. The main questions it aims to answer are: 1. Will Selective Laser Trabeculoplasty be an equally effective treatment option compared with 0.005% Latanoprost eyedrops in reducing Intraocular Pressure when used alone as first-line therapy in Nigerian patients with POAG and OHT? 2. Will Selective Laser Trabeculoplasty record a similar safety profile compared with 0.005% Latanoprost when used independently as a |
| Who can participate | Inclusion Criteria: 1. Patients aged 18years and above. 2. Patients newly diagnosed as Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT). 3. Patients with elevated IOP greater than 21mmHg (average of 3 measurements taken on 3 different clinic visits). 4. Patients categorized as early or moderate glaucoma POAG (cup -disc ratio 0.5 to 0.7, visual field analysis MD - 6dB to -12dB and disc damage likelihood score (DDLS) 5 to 7) on funduscopy, Optical coherence tomography, and fundus photograph 5. Patients who agree to participate in the study after informed consent. Exclusion Criteria: 1. A prior medical, surgical, or laser treatment for glaucoma 2. Patients diagnosed with primary congenital glaucoma or secondary glaucoma 3. Advanced glaucoma (CDR greater than 0.8, visual field a |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Lead sponsor | Lagos State Health Service Commission |
| Locations | Ikeja, Lagos, Nigeria |
| Start date | 2025-10-15 |
| NCT ID | NCT07310719 |
| Official listing | https://clinicaltrials.gov/study/NCT07310719 |